NICE asks BMS for more data before approving cancer drug

The National Institute or Health and Care Excellence (NICE) has published new draft guidance recommending that Bristol Myers Squibb, who manufacture nivolumab (Opdivo), provide more information on its drug’s effectiveness for treating Hodgkin lymphoma.

The independent appraisal committee recognised that nivolumab is an innovative and promising treatment, but concluded that the evidence presented was highly uncertain due to immature data and did not reflect how the drug would be used in UK clinical practice.

NICE requests that the company provides a revised analysis on the drug’s cost-effectiveness that takes into account the committee’s concerns at the next appraisal meeting.

The updated analyses should explore the use of UK data, for example from the Haematological Malignancy Research Network, in order to assess how effective nivolumab is when compared with standard care in the UK.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.